SII gets approval for H1N1 vaccine trial

SII gets approval for H1N1 vaccine trial

New Delhi: Pune-based Serum Institute of India (SII), the largest vaccine maker in the country, has received approval from India’s drugs controller to conduct clinical trials of its H1N1 vaccine.

SII’s vaccine will be the only live vaccine in the country and will be inhaled through the nose, as opposed to being injected.

This is the second indigenous vaccine trial to get the drug controller’s nod for clinical trial, the first being Zydus Cadila Health Care Ltd that got the approval on 4 January.

Close